More importantly, similar to the ABCP regimen, the MARIPOSA-2 trial (NCT04988295) is designed to assess the efficacy of the ALCP regimen (amivantamab, lazertinib, carboplatin and pemetrexed), ACP regimen (amivantamab, carboplatin and pemetrexed) and CP regimen (carboplatin and pemetrexed) in subjects with EGFR-mutant NSCLC after osimertinib failure. This evidence concerns the gene EGFR and non-small cell lung carcinoma.